President and Chief Executive Officer
Jon brings well over 30 years’ experience of successfully developing new medical technologies and building successful companies. Prior to Neograft, Jon was CEO of LumeRx, a venture-backed gastroenterology startup, VP of R&D and Operations at Biosphere Medical (acquired by Merit Medical); VP of R&D and Operations at Urologix (ULGX), and VP of R&D at Pfizer/Schneider (acquired by Boston Scientific). He cofounded Harbor Medical (acquired by Teleflex) and held several positions of increasing responsibility at Medi Tech (now Boston Scientific).
At LumeRx, Jon led the development and clinical testing of a novel light-based system to treat H pylori, the stomach bacteria that causes most stomach ulcers and cancers. Jon led a multinational team at Biosphere Medical that developed several generations of vascular embolic particles and delivery catheters. His team also achieved the first FDA approval of a transvascular treatment for uterine fibroids. At Urologix (ULGX), Jon spearheaded development of a transurethral microwave delivery system that treated BPH (benign prostate hyperplasia). Jon also led a multinational team at Pfizer/Schneider (acquired by Boston Scientific) developing interventional cardiology products. Jon’s team developed dozens of new products achieving revenues in the hundreds of millions within five years. Before that he cofounded Harbor Medical (acquired by Teleflex) that focused on vascular access devices. He began his career in R&D and operations at Medi Tech (now Boston Scientific). Jon has a B.S. in Physics from the University of Vermont.
Mohammed El-Kurdi, PhD.
Co-founder, Director, Research
Dr. El-Kurdi co-founded the company in 2009. He has been focused on bioengineering arterial vein grafts since 2000, beginning shortly after he joined a cardiovascular research team at the University of Pittsburgh’s McGowan Institute for Regenerative Medicine. His PhD work focused on Neograft’s core technology that formed the foundation of the company and its central intellectual property. This work also resulted in the first peer reviewed publication of the product. Several generations later, the company has evolved a product that delivers on the promise of his early research to produce a stable and self-supporting arterial vein graft.
In his early work, Dr. El-Kurdi combined fundamental principles in the fields of regenerative medicine and bioengineering to develop a viable solution for enhancing the durability of saphenous vein bypass grafts used in cardiac and vascular surgery. Through collaborations with clinicians and bioengineering research faculty, an approach to conformally coat a vein graft with a structural support using polymer electrospinning was conceived and proof-of-concept was demonstrated. After graduating, Dr. El-Kurdi completed a post-doctoral research fellowship at the McGowan Institute for Regenerative Medicine working in the field of heart valve tissue engineering. When seed funding was secured, Dr. El-Kurdi left academia to co-found Neograft Technologies, Inc.
In addition to his academic research, Dr. El-Kurdi also gained critical clinical experience through his work in the Artificial Heart Program at the University of Pittsburgh Medical Center. He served as a Biomedical Engineer in the program for six years, providing patient care and technical support to clinical staff for several FDA approved ventricular assist devices.
Vice President of Quality, Clinical & Regulatory
Steve is a seasoned quality, regulatory and clinical affairs executive with over 30 years of industry experience. Prior to Neograft, he was Director of Regulatory, Clinical Affairs and Quality at Insulet Corporation; Director of Clinical Operations at Boston Scientific; Director of Clinical Affairs at Phase Forward Corporation, and held several positions at PLC Medical Systems, including VP of R&D and Clinical Affairs. Steve has a B.S. in Physics from Bridgewater State University.
At Insulet Steve directed the Regulatory, Clinical and Quality teams working on state of the art insulin pump technology and was responsible for CE mark, ISO and FDA submissions, approvals and audits. At Boston Scientific Steve directed the clinical personnel who staffed the clinical study teams working towards approvals for new and expanding product lines ranging from cardiac stents to urology devices. At Phase Forward Steve directed teams responsible for implementing Electronic Data Capture (EDC) versions of clinical studies for some of the largest drug and device companies in the world. While at PLC Medical Systems Steve was responsible for the development and approval of revolutionary laser devices used in cardiac surgery as well as standard multidisciplinary medical lasers and accessories.
Vice President, Engineering & Development
Dave is a product development expert with a track record of successful product development in the Medical Device, Consumer, Instrumentation and Robotics industries. Prior to Neograft, Dave was Director of Systems Engineering at Foliage, a product development company. Dave has held positions in engineering management at Teleflex Medical OEM, Hill-Rom, and Bard, as well as other companies in the semiconductor and product development market spaces.
At Foliage, Dave led product development engagements with Philips Healthcare, Varian, and Ikaria. At Teleflex, he led four engineering teams in separate locations in the development of a variety of medical devices for OEM customers. As part of the management team at Allen Medical Systems, Dave developed a product roadmap and led engineering teams to develop three new products, including a patented spinal surgery table. At Bard, Dave led the team developing Bard’s first PTFE graft and supported product development for the Marlex Mesh line of hernia repair products.
Dave has an MS in mechanical engineering from M.I.T.